Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation.
about
PPARs and the cardiovascular systemRamipril mitigates radiation-induced impairment of neurogenesis in the rat dentate gyrusInterleukin-4 inhibition of interleukin-1-induced expression of matrix metalloproteinase-3 (MMP-3) is independent of lipoxygenase and PPARgamma activation in human gingival fibroblasts.A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseasesRole of lectin-like oxidized low density lipoprotein-1 in fetoplacental vascular dysfunction in preeclampsiaA gene expression profile related to immune dampening in the tumor microenvironment is associated with poor prognosis in gastric adenocarcinoma.The discovery of LOX-1, its ligands and clinical significance.Salvianolic acid B suppresses maturation of human monocyte-derived dendritic cells by activating PPARγPleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.PPAR-gamma in the Cardiovascular SystemA review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma.Thiazolidinediones in type 2 diabetes: a cardiology perspective.Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice.The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?Association of scavenger receptors in adipose tissue with insulin resistance in nondiabetic humans.Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1.LOX-1 and angiotensin receptors, and their interplay.Therapeutic Potential of PPARγ Activation in Stroke.Oxidized LDL, LOX-1 and atherosclerosis.Peroxisome proliferator-activated receptor-γ and the endothelium: implications in cardiovascular disease.LOX-1, oxidative stress and inflammation: a novel mechanism for diabetic cardiovascular complications.Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.The lectin-like oxidized low-density lipoprotein receptor-1 as therapeutic target for atherosclerosis, inflammatory conditions and longevity.Molecular biology of atherosclerosis.Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.Leonurus sibiricus herb extract suppresses oxidative stress and ameliorates hypercholesterolemia in C57BL/6 mice and TNF-alpha induced expression of adhesion molecules and lectin-like oxidized LDL receptor-1 in human umbilical vein endothelial cellsFriend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.LOX-1 transcription.Protective Actions of PPAR-gamma Activation in Renal Endothelium.Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) transcriptional regulation by Oct-1 in human endothelial cells: implications for atherosclerosis.Red wine polyphenols prevent endothelial dysfunction induced by endothelin-1 in rat aorta: role of NADPH oxidase.Tumor necrosis factor-alpha-induced apoptosis of human coronary artery endothelial cells: modulation by the peroxisome proliferator-activated receptor-gamma ligand pioglitazone.Blockade of hypoxia-reoxygenation-mediated collagen type I expression and MMP activity by overexpression of TGF-beta1 delivered by AAV in mouse cardiomyocytes.The protective effects of taurine against early renal injury in STZ-induced diabetic rats, correlated with inhibition of renal LOX-1-mediated ICAM-1 expression.LOX-1 receptor blockade abrogates oxLDL-induced oxidative DNA damage and prevents activation of the transcriptional repressor Oct-1 in human coronary arterial endothelium.Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy.Comparison of Pioglitazone and Metformin Efficacy against Glucocorticoid Induced Atherosclerosis and Hepatic Steatosis in Insulin Resistant Rats.In-vivo antioxidant and anti-inflammatory activity of rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists in animal model of bronchial asthma.
P2860
Q24642728-86F32231-06B2-4DE4-8399-37914D773FFFQ28580234-DD593112-BF0E-4C50-AB7D-516C90A9B41EQ30830094-E536026D-8DD0-444F-9E97-010DD19DE2A1Q33789567-3434EB82-0D4E-47D0-837A-3F69D95F6505Q33944749-E4F7BFE8-FD0C-4AA4-A9FC-14C999E7148AQ34468633-984E8FDC-8202-4F52-A72B-2C38F3020AE8Q35475499-5C843B1B-A3B4-4E5C-A639-3200068C7817Q35635993-E36456ED-EE7E-419E-8D63-D091C9FE70D2Q36068458-F118DADF-E798-4A0D-81B3-4E12A51BC738Q36426786-302836B3-9B1D-42D8-BA12-3900D12F35D2Q36596873-01D0673E-CDAE-4769-A15C-01F3AA4EDE24Q36992256-662239CB-78D8-49F4-9A1C-1A16B67E8880Q37079967-BE797E8C-A30A-46A6-A560-163CAD4A5B48Q37242253-426791D4-CF2B-4EE5-A9E7-4D121F002C19Q37281187-8E44D9B0-5BDD-4301-B7B3-2A7756A4C59AQ37362674-BAD311C4-B4DE-4F13-9B79-4E5BBD4536DDQ37370209-621085CC-6051-42E0-958E-7D8DA37B715EQ37438687-67794F36-E9F1-48BA-92D9-AF7C0A9B07E7Q37921158-2511E3A5-2DBE-4F5F-AEC1-2AC93EE82364Q37930425-2C23498C-9D40-4FC2-9FE3-DDF85ED35D42Q37938848-4253C6AD-873F-445F-9432-FD02B552726DQ37943863-D90849CA-1F6B-4D11-AF9A-E49BCB120E3FQ37945097-EFBAF37B-AC66-452F-BA6B-1D011AA3FA50Q37957629-390896EE-F5F5-4A99-848D-1906E222C42DQ38112162-C9B292CB-3911-4B72-885C-440BCFF407FEQ38125279-3503A238-C6D5-4D00-9A89-50BF641C791FQ38460480-E40E0DA8-E85F-4978-931D-EC1B1C7B7C5FQ38488644-4FFC9C96-D2EF-41B7-8933-47D05415955CQ38890930-415F3CB5-3E88-4A4F-8B92-245BDBA44271Q39724003-434023ED-5FFF-4BDD-B4BA-1F855CE612C3Q42008239-6E95CCB5-7C99-4113-9AE7-48BD8921C705Q42484227-816DDB78-E311-4D7B-A527-0B8EE8DA60FBQ42846915-BBEAF494-A2BC-498B-9C6A-65CAED43E6BDQ44849937-194491E8-9221-4960-9DAC-334BBA66A3B3Q45868980-303A1192-4766-4679-A95E-41915524A7E4Q46367552-ECD4FDAC-50A3-4967-BD84-3A94ED11F2ECQ46662739-1D5593C8-DCCA-4873-A66C-D8BA2A3C1FCCQ46701051-CAF695A8-80BE-4633-B66A-9400A4C5A55DQ48002814-89A1505F-98C4-4B7F-8248-CCF0F66E0F6DQ53201459-C0D75058-DE00-4191-95A6-4D109DAA9981
P2860
Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Pioglitazone inhibits LOX-1 ex ...... superoxide radical generation.
@en
type
label
Pioglitazone inhibits LOX-1 ex ...... superoxide radical generation.
@en
prefLabel
Pioglitazone inhibits LOX-1 ex ...... superoxide radical generation.
@en
P2093
P1476
Pioglitazone inhibits LOX-1 ex ...... superoxide radical generation.
@en
P2093
Jawahar L Mehta
Jiawei Chen
P304
P356
10.1161/01.ATV.0000094411.98127.5F
P407
P577
2003-09-04T00:00:00Z